Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02489526
Other study ID # VVZ149-POP-P2-US001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 28, 2015
Est. completion date August 15, 2016

Study information

Verified date March 2019
Source Vivozon, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, placebo-controlled study.


Description:

VVZ-149 is a dual antagonist of GlyT2 and 5HT2A. GlyT2 blockage increases inhibitory synaptic transmission by glycine in the spinal cord, resulting in a reduction of pain transmissions to the brain. 5HT2A blockage decreases descending serotonergic facilitatory modulation on pain transmission by the brain and reduces nociceptor activation in peripheral nerves, which are primary sources of pain in post-surgical pain. VVZ-149 has been shown to have comparable efficacy to morphine in well controlled (blind, complete randomization with a positive control) animal studies using rat models of post-operative pain and formalin-induced pain. The PK/PD study in animals indicates that therapeutic plasma concentration in human subjects will be 600-1,900 ng/ml. A clinical Phase 1 study performed in healthy subjects has shown no clinically significant adverse events up to a plasma concentration level of 3,261 ng/ml other than brief symptoms of mild nausea or dizziness, and mild somnolence when the plasma exposure level is more than 2,000 ng/ml.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 15, 2016
Est. primary completion date August 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Men and women age between 18-70, inclusive.

2. Pain intensity (NRS) =4 at initial post-operative measurement in PACU.

3. Subjects undergoing planned laparoscopic colorectal surgery.

4. Ability to provide written informed consent.

5. Ability to understand study procedures and communicate clearly with the investigator and staff.

6. American Society of Anesthesiologists (ASA) risk class of I to III.

Exclusion Criteria:

< Surgical Factors >

1. Emergency or unplanned surgery.

2. Repeat operation (e.g., previous surgery within 30 days for same condition).

3. Cancer-related condition causing preoperative pain in site of surgery.

< Subject Characteristics >

4. Women with childbearing potential (Women age 18-55 must undergo pregnancy test).

5. Women who are pregnant or breastfeeding.

6. Chronic pain diagnosis (e.g., ongoing pain at baseline with NRS = 4/10).

7. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or depression) Subjects who take stable doses (same dose >30 days) of antidepressants and anti-anxiety drugs may be included.

8. Unstable or acute medical condition (e.g., unstable angina, congestive heart failure, renal failure, hepatic failure, AIDS).

< Drug, Alcohol, and Pharmacological Considerations >

9. Renal or hepatic impairment.

10. History of alcohol, opiate or other drug abuse or dependence within 12 months prior to Screening (TICS alcohol/drug screen will be performed at Screening).

11. Ongoing or recent (within 30 days prior to surgery) use of steroids, opioids, or antipsychotics.

12. Alcohol consumption within 24 hours of surgery.

13. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 24 hours of surgery.

14. Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to surgery.

< Anesthetic and Other Exclusion Considerations >

15. Use of neuraxial or regional anesthesia related to the surgery.

16. Use of local anesthetic wound infiltration > 20 ml of 1% lidocaine

17. Use of ketamine, gabapentin, pregabalin, or lidocaine (>1 mg/kg) intra or peri-operatively, or within 24 hours of surgery.

18. Subjects with known allergies to hydromorphone.

19. Subjects who received another investigational drug within 30 days of scheduled surgery.

20. Subjects who have long PR (>200 msec) or prolonged QTc (> 450 msec) at Screening or on an EKG done immediately prior to dosing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VVZ-149 Injections
Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
Placebo
Placebo group will receive the corresponding amount of placebo.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Vivozon, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sum of Pain Intensity Difference over 8-hours post-dose (SPID8) SPID8 using Numerical Pain Rating Scale (NRS, 0-10) measured up to 8 hours post-dose 8 hours post-dose
Secondary Difference of Opioid Consumption between Study Groups 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 hours post-dose
Secondary Change of Pain Intensity (NRS) 9 and 24 hours post-dose
Secondary Change of Pain Relief (PR) assessed using a 6-point categorical scale 9 and 24 hours post-dose
Secondary Comparison of Global Measurement of Subject Satisfaction between Study Groups 8 and 24 hours post-dose
Secondary Change of Richmond Agitation-Sedation Scale 9 and 24 hours post-dose
Secondary Change of Incidence of Postoperative Nausea and Vomiting 8 and 24 hours post-dose
See also
  Status Clinical Trial Phase
Terminated NCT05146453 - Sternotomies and PectoIntercostal Fascia Blocks in Fast-Track Cardiac Anesthesiology Phase 4
Completed NCT05635916 - Trial of Liposomal Bupivacaine for TKA Phase 4
Recruiting NCT06028126 - Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial N/A
Not yet recruiting NCT03591172 - Using Three Different Final Irrigants and Showing Their Effects on the Success of Revascularization N/A
Completed NCT01686802 - Post-operative Oral Morphine Versus Ibuprofen Phase 2
Completed NCT01667445 - Evaluation of the Use of Spinal Epimorph in Total Knee Arthroplasty Phase 4
Completed NCT01444924 - Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery Phase 2
Completed NCT00830089 - Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery N/A
Completed NCT00968955 - Effect of Local Infiltration Analgesia in Total Hip Arthroplasty Phase 4
Terminated NCT00875862 - Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks Phase 4
Completed NCT00847093 - LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery Phase 4
Completed NCT00390312 - Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction Phase 2
Recruiting NCT05278494 - Dextromethorphan for Treatment of Postoperative Pain N/A
Recruiting NCT05973045 - Investigation of the Effect of Distention Medium Temperature on Image Quality, Hyponatremia Risk, and Post-operative Pain in Operative Hysteroscopy N/A
Not yet recruiting NCT04999670 - Fascial Closure and Post-caesarean Pain N/A
Enrolling by invitation NCT04346407 - Dronabinol for Post-operative Pain After Lumbar Fusion Phase 4
Completed NCT03635515 - Occurrence of Post-op Pain Following Gentlewave N/A
Terminated NCT03201809 - Comparison of Preoperative Ultrasound Guided Pectoralis Nerve Block Placement Versus Intra-operative Placement: A Prospective Randomized Trial N/A
Completed NCT03254056 - Fascial Closure Techniques Post-Operative Pain Laparoscopy N/A
Not yet recruiting NCT02555423 - The Effects of Serratus Plane Block Performed Under Direct Vision on Post-operative Pain in Breast Surgery N/A